Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Suicide Warnings For Valeant’s Siliq Could Hinder Access To Psoriasis Treatment

Executive Summary

While an FDA advisory committee unanimously supported approval of the plaque psoriasis drug brodalumab, several recommended a black box warning on suicide risk that could limit sales of the drug.


Related Content

Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market
Siliq US Approval Expected To Make Little Dent In Valeant Debt Mountain
Valeant’s Brodalumab Delayed By FDA As REMS Is Negotiated
Japan To Become First Market For Troubled Brodalumab
Sun Builds On Tildrakizumab Hopes With Almirall Pact
Another Black Cloud Douses Valeant's Sunlight
Post-Marketing Registry, Suicidality Warning Could Be Paradox For Siliq
Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts